Search results
AstraZeneca sets bold revenue target as CEO aims to double sales to $80 billion by 2030
Fortune· 26 minutes agoThe company, which generated $45.8 billion in revenue last year, will launch 20 new medicines by the end of the decade to meet the new total revenue target, Astra said Tuesday. The revenue goal ...
Posts Claim Falsely That AstraZeneca Is Withdrawing Its COVID Vaccine Because of Blood Clots
The Dispatch via Yahoo News· 5 days agoResearch by Airfinity, a U.K. data analytics company, in 2022 found that the AstraZeneca vaccine...
'I suffered a stroke after my AstraZeneca Covid vaccine'
Daily Express· 3 days agoAstraZeneca has since said that thrombocytopenia syndrome can be a “rare” side effect of the...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days agoAmgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe ...
FDA approves Amgen drug for tough-to-treat form of lung cancer
BioPharma Dive via Yahoo Finance· 4 days agoImdelltra, a bispecific antibody targeting a protein called DLL3, is cleared for use following...
How the love story between von der Leyen and Pfizer turned sour
Euronews via Yahoo News· 4 days agoFrom making her Europe’s vaccine saviour to becoming a skeleton in her closet: All the ebbs and...
Genetics Played a Role in Blood Clots Linked to COVID-19 Shots
Time Magazine· 5 days agoRare but deadly blood clots tied to Johnson & Johnson and AstraZeneca Plc’s Covid-19 shots were...
Earnings call: Compugen outlines progress and plans in Q1 2024 earnings By Investing.com
Investing.com· 11 hours agoThe company highlighted its successful transition of AI-predicted drug targets to clinical trials...
Iran's new president's link to COVID vaccine
Newsweek· 17 hours agoNew interim Iranian President Mohammad Mokhber received scrutiny for his role in the lack of development of a domestic vaccine at the height of the...
Blackstone-backed biotech launches with up to $300M for immune drug
BioPharma Dive via Yahoo Finance· 6 days agoAmgen and AstraZeneca entered the market first, after winning Food and Drug Administration approval...